283
Participants
Start Date
February 6, 2018
Primary Completion Date
April 11, 2019
Study Completion Date
January 8, 2020
romosozumab HCP administration with PFS
210 mg romosozumab SC QM by HCP administration with 2 PFS
romosozumab self-administration with AI/Pen
210 mg romosozumab SC QM by self-administration with 2 AI/Pens
Research Site, Great Neck
Research Site, Duncansville
Research Site, Wyomissing
Research Site, Chesapeake
Research Site, Danville
Research Site, Charlotte
Research Site, Spartanburg
Research Site, Summerville
Research Site, Atlanta
Research Site, Atlanta
Research Site, South Miami
Research Site, Delray Beach
Research Site, Birmingham
Research Site, Birmingham
Research Site, Tuscaloosa
Research Site, Huntsville
Research Site, Cincinnati
Research Site, Franklin
Research Site, Fargo
Research Site, Bridgeton
Research Site, Springfield
Research Site, San Antonio
Research Site, Denver
Research Site, Golden
Research Site, Salt Lake City
Research Site, Mesa
Research Site, Chandler
Research Site, Las Vegas
Research Site, Cypress
Research Site, Glendale
Research Site, Laguna Hills
Research Site, Tustin
Research Site, Fullerton
Research Site, Santa Maria
Research Site, Renton
Research Site, Bialystok
Research Site, Lodz
Research Site, Świdnik
Research Site, Warsaw
Research Site, Chorley
Research Site, Edinburgh
Research Site, Liverpool
Research Site, London
Research Site, Manchester
Research Site, Northwood
Research Site, Romford
Lead Sponsor
Amgen
INDUSTRY